3 results match your criteria: "Department of Urology Mayo Clinic Rochester Minnesota USA.[Affiliation]"
Background: Neoadjuvant platinum-based chemotherapy offers a modest survival advantage in muscle-invasive bladder cancer (MIBC) for patients with pathologic response. B7-H3 (), an immune checkpoint overexpressed in various cancers, including urothelial-cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum-based chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the prevalence of radiographic progression (rDP) in men with prostate cancer who had very low prostate-specific antigen (PSA) levels using C-11 choline PET imaging.
- Out of 1323 patients with rDP, 220 (16.6%) exhibited this progression while their PSA was under 0.5 ng/mL, with 78% subsequently developing castration-resistant prostate cancer (CRPC).
- Key findings indicate that common sites of rDP included lymph nodes and bones, with factors like older age and CRPC status linked to poorer survival rates, as 46% of this low PSA rDP group died during follow-up.
Objective: To evaluate the relationship between pre-operative PSA value, Ga-prostate-specific-membrane-antigen (PSMA) PET performance and oncologic outcomes after salvage lymph node dissection (sLND) for biochemical recurrent prostate cancer (PCa).
Patients And Methods: The study included 164 patients diagnosed with ≤2 pelvic lymph-node recurrence(s) of PCa documented on Ga-PSMA PET scan and treated with pelvic ± retroperitoneal sLND at 11 high-volume centres between 2012 and 2019. Pathologic findings were correlated to PSA values at time of sLND, categorized in early (<0.